All In Biotech

Drug Trial Radar · NCT06112314

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301

Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

680

Planned (sponsor's estimate)

Start

Jun 5, 2024

Primary completion

Oct 16, 2027

Study completion Oct 16, 2027

Sponsor

Lead sponsor
Immunocore LtdIndustry
Sponsor type
Industry
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.

Conditions

  • Advanced Melanoma

Interventions

  • BrenetafuspDrug

    Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.

  • NivolumabDrug

    Concentrate for solution for infusion at a unit dose of 10 mg/mL.

  • Nivolumab + RelatlimabDrug

    Concentrate for solution for infusion at a unit dose of 16 mg/mL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to ~45 months

Locations

211 sites in 26 countries. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona · Recruiting

  • University of California - San Diego

    La Jolla, California · Recruiting

  • The Angeles Clinic and Research Institute- West Los Angeles

    Los Angeles, California · Recruiting

  • ESC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology

    Los Angeles, California · Recruiting

  • Stanford Cancer Institute - Stanford Cancer Center Palo Alto

    Palo Alto, California · Completed

  • Saint John's Health Center - John Wayne Cancer Institute (JWCI)

    Santa Monica, California · Recruiting

  • University of Colorado, Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • The Melanoma & Skin Cancer Institute

    Denver, Colorado · Recruiting

  • UConn Health-Farmington (University of Connecticut Health Center (UCHC))

    Farmington, Connecticut · Completed

  • Georgetown University

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • University of Miami Health System-Sylvester Comprehensive Cancer Center-Miami

    Miami, Florida · Recruiting

  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center - NMDTI

    Chicago, Illinois · Recruiting

  • The University of Kansas Cancer Center (KUCC) - Westwood

    Westwood, Kansas · Recruiting

  • St. Elizabeth Healthcare - Edgewood

    Edgewood, Kentucky · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Cancer Center - Michigan

    Detroit, Michigan · Recruiting

  • Allina Health Cancer Institute - Minneapolis

    Minneapolis, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Completed

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Northwell Health Cancer Institute

    Lake Success, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Completed

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Prisma Health Cancer Institute

    Greenville, South Carolina · Recruiting

  • Spartanburg Regional Healthcare System - Spartanburg Medical Center (SMC)

    Spartanburg, South Carolina · Recruiting

  • The University of Tennessee - Knoxville (UTK)

    Knoxville, Tennessee · Recruiting

  • Sarah Cannon Research Institute: USA/TN

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology, PLLC

    Nashville, Tennessee · Recruiting

  • University of Texas Southwestern

    Dallas, Texas · Recruiting

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • UVA Health-UVA Emily Couric Clinical Cancer Center

    Charlottesville, Virginia · Recruiting

  • Virginia Commonwealth University (VCU) - Massey Cancer Center

    Richmond, Virginia · Recruiting

  • Swedish Medical Center - Swedish Cancer Institute (SCI) - First Hill Campus

    Seattle, Washington · Recruiting

  • Hospital Italiano de Buenos Aires (HIBA)

    Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming

    CABA, Argentina · Recruiting

  • CEMAIC (Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

    Córdoba, Argentina · Recruiting

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.